RA Capital Management’s Biogen BIIB Stock Holding History

RA Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,184,456	Closed	-$230M	–	91
2024 Q3	$230M	Buy	1,184,456 +202,317	+21%	+$42.3M	2.65%	10
2024 Q2	$228M	Buy	982,139 +241,412	+33%	+$52.5M	3.01%	6
2024 Q1	$160M	Buy	740,727 +207,835	+39%	+$48.7M	2.03%	13
2023 Q4	$138M	Hold	532,892	–	–	2.15%	9
2023 Q3	$137M	Hold	532,892	–	–	2.7%	6
2023 Q2	$152M	Hold	532,892	–	–	2.87%	6
2023 Q1	$148M	Hold	532,892	–	–	3.35%	6
2022 Q4	$148M	Sell	532,892 -404,657	-43%	-$114M	2.99%	9
2022 Q3	$250M	Buy	937,549 +210,525	+29%	+$44.7M	5.34%	2
2022 Q2	$148M	Hold	727,024	–	–	3.95%	2
2022 Q1	$153M	Buy	+727,024	New	+$158M	3.34%	2
2015 Q3	–	Sell	-2,600	Closed	-$1.05M	–	54
2015 Q2	$1.05M	Hold	2,600	–	–	0.11%	52
2015 Q1	$1.1M	Hold	2,600	–	–	0.11%	51
2014 Q4	$883K	Hold	2,600	–	–	0.09%	46
2014 Q3	$860K	Buy	+2,600	New	+$857K	0.1%	38

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RA Capital Management's BIIB Position: Q4 2024 in Review

RA Capital Management sold out of Biogen (BIIB) in Q4 2024, closing a stake of 1,184,456 shares — an estimated $230M sold.

RA Capital Management first reported a position in BIIB in Q3 2014 and held it in 15 quarters. The position peaked at $250M in Q3 2022. 874 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

RA Capital Management reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
RA Capital Management sold 1,184,456 Biogen shares in Q4 2024, an estimated $230M.
RA Capital Management first reported a position in Biogen in Q3 2014 and held it in 15 quarters.
RA Capital Management's Biogen position peaked at $250M in Q3 2022.
874 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on RA Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.